Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 187, Issue 8, 2011, Pages 4310-4318

  Schweingruber, Nils ^a,b   Haine, Axel ^a   Tiede, Karsten ^a   Karabinskaya, Anna ^b   Van Den Brandt, Jens ^b,f   Wüst, Simone ^a,g   Metselaar, Josbert M ^c   Gold, Ralf ^d   Tuckermann, Jan P ^e   Reichardt, Holger M ^b   Lühder, Fred ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c Enceladus Pharmaceuticals   (Netherlands)

^d ST JOSEF HOSPITAL   (Germany)

^e FRITZ LIPMANN INSTITUTE   (Germany)

^f Medical University of Greifswald   (Germany)

^g NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DEXA RATIO PHARM; DEXAMETHASONE SODIUM PHOSPHATE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHYLPREDNISOLONE SODIUM SUCCINATE; NITRIC OXIDE; PREDNISOLONE HEMISUCCINATE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL ACTIVITY; CELL FUNCTION; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENCAPSULATION; GENETIC ASSOCIATION; INTRACELLULAR SPACE; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SINGLE DRUG DOSE; T LYMPHOCYTE; THERAPY EFFECT; UPREGULATION;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION; GLUCOCORTICOIDS; IMMUNOHISTOCHEMISTRY; LIPOSOMES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, GLUCOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 80054764032     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101604     Document Type: Article

References (45)

1. Donati, G. 2007. Emerging therapies for neovascular age-related macular degeneration: state of the art. Ophthalmologica 221: 366-377. (Pubitemid 47616113)
2. Hench, P. 1950. Effects of cortisone in the rheumatic diseases. Lancet 2: 483-484.
3. Scott, D. L., F. Wolfe, and T. W. J. Huizinga. 2010. Rheumatoid arthritis. Lancet 376: 1094-1108.
4. Milligan, N. M., R. Newcombe, D. A. S. Compston; Clinical Effects. 1987. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J. Neurol. Neurosurg. Psychiatry 50: 511-516. (Pubitemid 17067536)
5. Hochhaus, G., M. A. González, R. J. Dockhorn, J. Shilstone, and J. Karafilidis. 2002. A new solution-based intranasal triamcinolone acetonide formulation in patients with perennial allergic rhinitis: how does the pharmacokinetic/pharmacodynamic profile for cortisol suppression compare with an aqueous suspensionbased formulation? J. Clin. Pharmacol. 42: 662-669. (Pubitemid 34547450)
6. Woodle, M. C., M. S. Newman, and J. A. Cohen. 1994. Sterically stabilized liposomes: physical and biological properties. J. Drug Target. 2: 397-403.
7. Allen, T. M., and C. Hansen. 1991. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta 1068: 133-141.
8. O'Brien, M. E. 2008. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 19: 1-7. (Pubitemid 350190962)
9. Metselaar, J. M., M. H. M. Wauben, J. P. A. Wagenaar-Hilbers, O. C. Boerman, and G. Storm. 2003. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. 48: 2059-2066. (Pubitemid 36828702)
10. Schmidt, J., J. M. Metselaar, M. H. M. Wauben, K. V. Toyka, G. Storm, and R. Gold. 2003. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 126: 1895-1904. (Pubitemid 36917348)
11. Linker, R. A., C. Weller, F. Lühder, A. Mohr, J. Schmidt, M. Knauth, J. M. Metselaar, and R. Gold. 2008. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp. Neurol. 211: 397-406.
12. Herold, M. J., K. G. McPherson, and H. M. Reichardt. 2006. Glucocorticoids in T cell apoptosis and function. Cell. Mol. Life Sci. 63: 60-72. (Pubitemid 43100281)
13. Caramori, G., and I. Adcock. 2005. Anti-inflammatory mechanisms of glucocorticoids targeting granulocytes. Curr. Drug Targets Inflamm. Allergy 4: 455-463. (Pubitemid 41052410)
14. Tuckermann, J. P., A. Kleiman, K. G. McPherson, and H. M. Reichardt. 2005. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit. Rev. Clin. Lab. Sci. 42: 71-104. (Pubitemid 41656710)
15. Lühder, F., and H. M. Reichardt. 2009. Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy. Crit. Rev. Immunol. 29: 255-273.
16. Hafezi-Moghadam, A., T. Simoncini, Z. Q. Yang, F. P. Limbourg, J. C. Plumier, M. C. Rebsamen, C. M. Hsieh, D. S. Chui, K. L. Thomas, A. J. Prorock, et al. 2002. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat. Med. 8: 473-479. (Pubitemid 34546749)
17. Gold, R., F. Buttgereit, and K. V. Toyka. 2001. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J. Neuroimmunol. 117: 1-8. (Pubitemid 32595488)
18. Buttgereit, F., R. H. Straub, M. Wehling, and G. R. Burmester. 2004. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 50: 3408-3417. (Pubitemid 39488664)
19. Gold, R., C. Linington, and H. Lassmann. 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953-1971. (Pubitemid 44289062)
20. Wüst, S., J. van den Brandt, D. Tischner, A. Kleiman, J. P. Tuckermann, R. Gold, F. Lühder, and H. M. Reichardt. 2008. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J. Immunol. 180: 8434-8443.
21. Amselem, S., R. Cohen, and Y. Barenholz. 1993. In vitro tests to predict in vivo performance of liposomal dosage forms. Chem. Phys. Lipids 64: 219-237. (Pubitemid 23290875)
22. Lim, H. Y., N. Müller, M. J. Herold, J. van den Brandt, and H. M. Reichardt. 2007. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 122: 47-53. (Pubitemid 47222594)
23. Reichardt, H. M., J. P. Tuckermann, M. Göttlicher, M. Vujic, F. Weih, P. Angel, P. Herrlich, and G. Schütz. 2001. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 20: 7168-7173. (Pubitemid 34062308)
24. Chan, A., T. Magnus, and R. Gold. 2001. Phagocytosis of apoptotic inflammatory cells by microglia and modulation by different cytokines: mechanism for removal of apoptotic cells in the inflamed nervous system. Glia 33: 87-95. (Pubitemid 32102819)
25. Kruse, N., S. Cetin, A. Chan, R. Gold, and F. Lühder. 2007. Differential expression of BDNF mRNA splice variants in mouse brain and immune cells. J. Neuroimmunol. 182: 13-21. (Pubitemid 46026702)
26. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
27. Uhmann, A., J. van den Brandt, K. Dittmann, I. Hess, R. Dressel, C. Binder, F. Lühder, H. Christiansen, M. Fassnacht, A. Bhandoola, et al. 2011. T cell development critically depends on prethymic stromal patched expression. J. Immunol. 186: 3383-3391.
28. Wang, D. P., N. Müller, K. G. McPherson, and H. M. Reichardt. 2006. Glucocorticoids engage different signal transduction pathways to induce apoptosis in thymocytes and mature T cells. J. Immunol. 176: 1695-1702. (Pubitemid 43134314)
29. Tuckermann, J. P., A. Kleiman, R. Moriggl, R. Spanbroek, A. Neumann, A. Illing, B. E. Clausen, B. Stride, I. Förster, A. J. R. Habenicht, et al. 2007. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J. Clin. Invest. 117: 1381-1390. (Pubitemid 46718426)
30. Sherman, M. P., J. M. Griscavage, and L. J. Ignarro. 1992. Nitric oxide-mediated neuronal injury in multiple sclerosis. Med. Hypotheses 39: 143-146.
31. Ciccone, A., S. Beretta, F. Brusaferri, I. Galea, A. Protti, and C. Spreafico. 2008. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst. Rev. 1: CD006264.
32. Chan, J., E. J. Ban, K. H. Chun, S. Wang, J. McQualter, C. Bernard, B. H. Toh, and F. Alderuccio. 2008. Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. Autoimmunity 41: 405-413. (Pubitemid 351891202)
33. Crielaard, B. J., T. Lammers, M. E. Morgan, L. Chaabane, S. Carboni, B. Greco, P. Zaratin, A. D. Kraneveld, and G. Storm. 2011. Macrophages and liposomes in inflammatory disease: Friends or foes? Int. J. Pharm. 416: 499-506.
34. Anderson, R., A. Franch, M. Castell, F. J. Perez-Cano, R. Bräuer, D. Pohlers, M. Gajda, A. P. Siskos, T. Katsila, C. Tamvakopoulos, et al. 2010. Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of watersoluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Res. Ther. 12: R147.
35. Metselaar, J. M., W. B. van den Berg, A. E. M. Holthuysen, M. H. M. Wauben, G. Storm, and P. L. E. M. van Lent. 2004. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann. Rheum. Dis. 63: 348-353. (Pubitemid 38453298)
36. Farias, A. S., C. de la Hoz, F. R. Castro, E. C. Oliveira, J. R. Ribeiro dos Reis, J. S. Silva, F. Langone, and L. M. B. Santos. 2007. Nitric oxide and TNFalpha effects in experimental autoimmune encephalomyelitis demyelination. Neuroimmunomodulation 14: 32-38. (Pubitemid 47340633)
37. Aboul-Enein, F., P. Weiser, R. Hoftberger, H. Lassmann, and M. Bradl. 2006. Transient axonal injury in the absence of demyelination: a correlate of clinical disease in acute experimental autoimmune encephalomyelitis. Acta Neuropathol. 111: 539-547. (Pubitemid 43778958)
38. Mantovani, A., A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25: 677-686. (Pubitemid 39457982)
39. Diem, R., M. B. Sättler, D. Merkler, I. Demmer, K. Maier, C. Stadelmann, H. Ehrenreich, and M. Bähr. 2005. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 128: 375-385. (Pubitemid 40222606)
40. Reichardt, H. M., R. Gold, and F. Lühder. 2006. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Expert Rev. Neurother. 6: 1657-1670. (Pubitemid 44904011)
41. Sloka, J. S., and M. Stefanelli. 2005. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult. Scler. 11: 425-432. (Pubitemid 40984237)
42. Martinez, F. O., A. Sica, A. Mantovani, and M. Locati. 2008. Macrophage activation and polarization. Front. Biosci. 13: 453-461. (Pubitemid 351599757)
43. Ehrchen, J., L. Steinmüller, K. Barczyk, K. Tenbrock, W. Nacken, M. Eisenacher, U. Nordhues, C. Sorg, C. Sunderkötter, and J. Roth. 2007. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 109: 1265-1274. (Pubitemid 46220679)
44. Mikita, J., N. Dubourdieu-Cassagno, M. S. A. Deloire, A. Vekris, M. Biran, G. Raffard, B. Brochet, M. H. Canron, J. M. Franconi, C. Boiziau, and K. G. Petry. 2011. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult. Scler. 17: 2-15.
45. Boven, L. A., M. Van Meurs, M. Van Zwam, A. Wierenga-Wolf, R. Q. Hintzen, R. G. Boot, J. M. Aerts, S. Amor, E. E. Nieuwenhuis, and J. D. Laman. 2006. Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 129: 517-526. (Pubitemid 43164373)